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Introduction:
Meenal Kapoor, MD; DuPrey KM; Ahmed S MD; Mishriki YY MD
Ménétrier disease is a rare, acquired disease characterized by enlarged 
gastric folds in the fundus and body with foveolar hyperplasia, cystic 
dilation of gastric glands , reduced numbers of parietal and chief cells 
with hypochlorhydria and protein losing enteropathy. We present a case 




(Other names include Hypoalbuminemic hyperplastic gastropathy 
and hyperplastic hypersecretory gastropathy)
Prevalence:
Very rare with fewer that 400 cases worldwide
Clinical Manifestations:
 	 	 -	 	Epigastric	pain	-	65	percent	 	 	 	 	 	 	 -	 	Weight	loss	-	45	percent
 	 	 -	 Asthenia	-	60	percent		 	 	 	 	 	 	 	 	 -	 	Edema	-	38	percent
 	 	 -	 	Anorexia	-	45	percent          -	 	Vomiting	-	38	percent
Diagnosis:
•  Gross: Striking enlargement of gastric folds or rugae, confined to the body and fundus.
•  Histology: Extreme foveolar hyperplasia with glandular atrophy on a full thickness biopsy (or 
endoscopic snare or suction biopsy).
Treatment:
•  Octreotide has been shown to improve enteral protein loss. No clear data or study is available 
for duration of treatment. 
•  Case reports for treatment with a monoclonal antibody directed against the epidermal growth 
factor receptor (Erbitux).
• Surgical option with total gastrectomy.
Prognosis:
The natural history of Ménétrier’s disease is not well characterized. Scattered reports have 
demonstrated the evolution from Menetrier’s disease to gastric atrophy over four to eight 
years, with return of the serum albumin concentration to normal The risk of gastric cancer in 
patients with Ménétrier’s disease is uncertain, Other reports indicate that sepsis, vascular and/
or thromboembolic complications may be a greater threat to patients with Menetrier’s disease 
than malignant transformation. 
Chief Complaint:
A 41-year-old hispanic male with AIDS, chronic hepatitis C, and a history of ascending colitis 
with cecal ulcer, presented with 3-month history of unintentional weight loss of 20 pounds and 
diffuse pain in epigastrium and RUQ, with associated diarrhea, nausea, and vomiting.
Physical Examination:
Pertinent positives: Tenderness in epigastrium, and ascites with anasarca.
Investigations:
Laboratory data: Severe hypoalbuminemia (2.0gm/dL), hyponatremia (127 meq/dL), peripheral 
eosinophilia- 25%.
Ascitic fluid analysis: SAAG of <1.1.
Initial esophagogastroduodenoscopy (EGD) with superficial gastric biopsy: Findings consistent 
with eosinophilic gastritis. 
Stool studies: Occasional Charcot-leyden crystals, ova and parasites negative. 
CMV DNA: Negative.
Repeat EGD: Enlarged gastric fold in fundus and cardia with diffusely erythematous, nodular 
and friable mucosa.
Endoscopic ultrasound with full thickness gastric snare biopsy: Foveolar hyperplasia with 
superficial erosions associated with acute on chronic inflammation and sparse fundic glands 
with reactive changes (Fig. 1& 2).
Treatment:
Prednisone 40 mg + Octreotide 0.1 mg SQ BID for 5 days followed by monthly intramuscular 
injection. 
Albendazole 400 mg for 3 days for possibility of Ancylostoma caninum (empiric).
Discussion:
Overexpression of transforming growth factor alpha has been proposed to play a role in the 
pathophysiology of Ménétrier’s disease. Its levels are increased in the gastric mucosa of 
patients with Ménétrier’s disease. TGF-alpha is responsible for maintaining gastric homeostasis 
by inhibiting acid secretion while increasing gastric mucous production. HIV-1 tat gene product 
stimulates TGF-alpha production, which activates the EGF receptor. Our hypothesis states 
that overexpression of TGF-alpha by HIV can lead to gastric epithelial changes consistent with 
Ménétrier’s disease via the pathway shown (Fig. 4).
Figure 4. HIV induced upregulation of TGF-alpha, leading to Ménétrier disease. TGF: Tumor growth 
factor, PDX-1: Pancreatic and duodenal homeobox 1.
Our Hypothesis
Key Points:
•  Ménétrier disease is a rare cause of gastric rugal hypertrophy with protein losing enteropathy 
likely caused by elevated levels of  transforming growth factor-alpha  (TGF-α).
•  AIDS patients may have higher risk of Ménétrier disease due to HIV-1 tat gene related over 
production of TGF-α.
•  Ménétrier disease should be considered in an AIDS patient with abdominal pain and protein 
losing enteropathy who has no evidence of gastrointestinal CMV or H. pylori infection.
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